SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2022 / Cilt: 7 - Sayı: 3

The Attitudes of the Patients with the Multisystem Inflammatory Syndrome in Children Secondary to SARS-CoV-2 Regarding COVID-19 Vaccines

Çocuklarda COVID-19’a İkincil Gelişen Multisistemik İnflamatuar Sendrom Tanılı Hastaların COVID-19 Aşısına Karşı Tutumları

Eviç Zeynep AKGÜN
Dicle AYDIN
Hafize Emine SÖNMEZ
Kadir BABAOĞLU
Pages
468–472
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multisystem inflammatory syndrome (MIS-C) in children is an abnormal immune response that occurs after exposure to SARS-CoV-2.
📊
Key Findings & Data:To our knowledge, there is no study demonstrating the efficacy and safety of the BNT162b2 mRNA vaccine in children who were diagnosed with MIS-C previously.
💡
Conclusion & Impact:In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Aşı güvenliği · BNT162b2 mRNA aşısı · çocuklarda multisistemik inflamatuar sendrom

Abstract

Objective: Multisystem inflammatory syndrome (MIS-C) in children is an abnormal immune response that occurs after exposure to SARS-CoV-2. To our knowledge, there is no study demonstrating the efficacy and safety of the BNT162b2 mRNA vaccine in children who were diagnosed with MIS-C previously. In this study, we aimed to present the attitudes of MIS-C patients over the age of 12 years towards the COVID-19 vaccine, and the side effects of the vaccine in vaccinated patients.

Özet

Amaç: Çocuklarda multisistemik inflamatuar sendrom (MIS-C); SARS-CoV-2 ile enfekte olduktan sonra ortaya çıkan anormal bir bağışıklık yanıtıdır. Bu hastalarda BNT162b2 mRNA aşısının etkinliğini ve güvenliğini ortaya koyan bir çalışma yoktur. Bu çalışmada MIS-C tanısı almış 12 yaşın üzerindeki hastalarımızın COVID-19 aşısına karşı tutumları ve eğer aşılandılarsa gelişen yan etkileri sunmayı amaçladık.

🔖

Cite This Article

AKGÜN, E. Z., AYDIN, D., SÖNMEZ, H. E., BABAOĞLU, K. (2022). The Attitudes of the Patients with the Multisystem Inflammatory Syndrome in Children Secondary to SARS-CoV-2 Regarding COVID-19 Vaccines. Online Türk Sağlık Bilimleri Dergisi, Cilt: 7 - Sayı: 3, 468–472. https://ajindex.com/articles/585432

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680 Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756 Centers for Disease Control andPrevention. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Corona virus Disease 2019 (COVID-19) 2020. https://emergency.cdc.gov/han/2020/han00432.asp. Accessed March 20, 2022.
  2. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1755–1760. doi:10.15585/mmwr.mm705152a1 Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: A surveillance investigation. Lancet Child Adolesc Health. 2022;6(5): 3030-312. doi:10.1016/S2352-4642(22)00028-1
  3. Levy M, Recher M, Hubert H, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327(3):281-283. doi:10.1001/jama.2021.23262 Zambrano LD, Newhams MM, Olson SM, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52–58. doi:10.155585/mmwr.mm7102e1 Buchhorn R, Meyer C, Schulze-Forster K, Junker J, Heidecke H. Autoantibody release in children after corona virus mRNA vaccination: A risk factor of multisystem inflammatory syndrome? Vaccines (Basel). 2021;9(11):1353. doi:10.3390/vaccines9111353 Chin SE, Bhavsar SM, Corson A, Ghersin ZJ, Kim HS. Cardiac complications associated with COVID-19, MIS-C, and mRNA COVID-19 vaccination. Pediatr Cardiol. 2022;43(3):483-488. doi:10.1007/s00246-022-02851-x Centers for Disease Control and Prevention. The vaccine adverse event reporting system (VAERS) results 2021. https://wonder.cdc.gov/vaers.html. Accessed December 2, 2021.
  4. Rostad CA, Chahroudi A, Mantus G, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics. 2020;146:e2020018242. doi:10.1542/peds.2020-018242
  5. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric severe acute respiratory syndrome coronav